HomeCompareHKMPF vs NOBL

HKMPF vs NOBL: Dividend Comparison 2026

HKMPF yields 4.85% · NOBL yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HKMPF wins by $302.53M in total portfolio value
10 years
HKMPF
HKMPF
● Live price
4.85%
Share price
$17.30
Annual div
$0.84
5Y div CAGR
85.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$302.56M
Annual income
$279,218,818.50
Full HKMPF calculator →
NOBL
NOBL
● Live price
2.14%
Share price
$106.01
Annual div
$2.27
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.8K
Annual income
$246.19
Full NOBL calculator →

Portfolio growth — HKMPF vs NOBL

📍 HKMPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHKMPFNOBL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HKMPF + NOBL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HKMPF pays
NOBL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HKMPF
Annual income on $10K today (after 15% tax)
$412.45/yr
After 10yr DRIP, annual income (after tax)
$237,335,995.73/yr
NOBL
Annual income on $10K today (after 15% tax)
$182.19/yr
After 10yr DRIP, annual income (after tax)
$209.26/yr
At 15% tax rate, HKMPF beats the other by $237,335,786.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HKMPF + NOBL for your $10,000?

HKMPF: 50%NOBL: 50%
100% NOBL50/50100% HKMPF
Portfolio after 10yr
$151.29M
Annual income
$139,609,532.34/yr
Blended yield
92.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on HKMPF right now

HKMPF
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
3.5
Piotroski
7/9
NOBL
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HKMPF buys
0
NOBL buys
0
No recent congressional trades found for HKMPF or NOBL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHKMPFNOBL
Forward yield4.85%2.14%
Annual dividend / share$0.84$2.27
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR85.6%0%
Portfolio after 10y$302.56M$22.8K
Annual income after 10y$279,218,818.50$246.19
Total dividends collected$300.79M$2.3K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: HKMPF vs NOBL ($10,000, DRIP)

YearHKMPF PortfolioHKMPF Income/yrNOBL PortfolioNOBL Income/yrGap
1← crossover$11,601$900.60$10,914$214.34+$687.00HKMPF
2$14,225$1,812.21$11,897$218.63+$2.3KHKMPF
3$19,075$3,854.51$12,952$222.72+$6.1KHKMPF
4$29,376$8,965.67$14,086$226.62+$15.3KHKMPF
5$55,382$23,949.87$15,302$230.33+$40.1KHKMPF
6$137,579$78,320.34$16,607$233.85+$121.0KHKMPF
7$484,693$337,482.73$18,007$237.18+$466.7KHKMPF
8$2,580,955$2,062,333.89$19,508$240.35+$2.56MHKMPF
9$21,810,404$19,048,782.00$21,116$243.35+$21.79MHKMPF
10$302,555,951$279,218,818.50$22,841$246.19+$302.53MHKMPF

HKMPF vs NOBL: Complete Analysis 2026

HKMPFStock

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Full HKMPF Calculator →

NOBLETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →
📬

Get this HKMPF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HKMPF vs SCHDHKMPF vs JEPIHKMPF vs OHKMPF vs KOHKMPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.